Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Cited by (1,078)

Items 401–500 of 1,078

1. Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
   Ashley M. Holder, Aikaterini Dedeilia, Kailan Sierra-Davidson, Sonia Cohen, David Liu, Aparna R. Parikh, Genevieve Marie Boland · 2024 · Nature reviews. Cancer
2. Harnessing the immune system to improve cancer therapy
   Nikos E. Papaioannou, Ourania V. Beniata, Panagiotis Vitsos, Ourania Tsitsilonis, Pinelopi Samara · 2016 · Annals of Translational Medicine
3. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma
   Diem, S, Kasenda, B, Spain, L, Martin-Liberal, J, Marconcini, R, Gore, M, Larkin, J · 2016 · British Journal of Cancer
4. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model
   Ruea-Yea Huang, Cheryl Eppolito, Shashikant Lele, Protul A. Shrikant, Junko Matsuzaki, Kunle O. Odunsi · 2015 · Oncotarget
5. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC
   Lillian L. Siu, Caroline Even, Ricard Mesı́a, Éva Remenár, Amaury Daste, Jean‐Pierre Delord, Jürgen Krauß, Nabil F. Saba, Lisle M. Nabell, Neal Ready et al. · 2018 · JAMA Oncology
6. Delivering safer immunotherapies for cancer
   Lauren E. Milling, Yuan Zhang, Darrell J. Irvine · 2017 · Advanced Drug Delivery Reviews
7. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
   Farshad Nassiri, Vikas S. Patil, Leeor S. Yefet, Olivia Singh, Jeff Liu, Rachel M. A. Dang, Takafumi N. Yamaguchi, Mariza Daras, Timothy Francis Cloughesy, Howard Colman et al. · 2023 · Nature Medicine
8. T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants
   Daniel Hirschhorn, Sadna Budhu, Lukas Kraehenbuehl, Mathieu Gigoux, David Schröder, Andrew T. Chow, Jacob M. Ricca, Billel Gasmi, Olivier De Henau, Levi Mark B Mangarin et al. · 2023 · Cell
9. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort
   Shelley Ji Eun Hwang, Giuliana Carlos, Deepal Wakade, Karen Byth, Benjamin Y. Kong, Shaun Chou, Matteo Salvatore Carlino, Richard F. Kefford, Pablo Fernández‐Peñas · 2016 · Journal of the American Academy of Dermatology
10. INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology
    Eddy W. Yue, Richard B. Sparks, Padmaja K Polam, Dilip Modi, Brent D. Douty, Brian R. Wayland, Brian M. Glass, Amy G. Takvorian, Joseph Glenn, Wenyu Zhu et al. · 2017 · ACS Medicinal Chemistry Letters
11. The immune system and cancer evasion strategies: therapeutic concepts
    Muenst, S., Läubli, H., Soysal, S. D., Zippelius, A., Tzankov, A., Hoeller, S. · 2016 · Journal of Internal Medicine
12. The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors
    Harish Shanthanu Seethapathy, Sophia J. Zhao, Donald F. Chute, Leyre Zubiri, Yaa D. Oppong, Ian A. Strohbehn, Frank B. Cortazar, David E. Leaf, Meghan J. Mooradian, Alexandra–Chloé Villani et al. · 2019 · Clinical Journal of the American Society of Nephrology
13. Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression
    Yunzhou Pu, Qing Ji · 2022 · Frontiers in Immunology
14. The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma
    Alexander Noor Shoushtari, Rodrigo Ramella Munhoz, Deborah Kuk, Patrick Alexander Ott, Douglas Buckner Johnson, Katy K. Tsai, Suthee Rapisuwon, Zeynep Eroglu, Ryan Joseph Sullivan, Jason J. Luke et al. · 2016 · Cancer
15. Drug induced liver injury: an update
    Miren García‐Cortés, Mercedes Robles‐Díaz, Camilla M. Stephens, Aida Ortega‐Alonso, M. Isabel Lucena, Raúl J. Andrade · 2020 · Archives of Toxicology
16. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies
    Ryan Joseph Sullivan, Jeffrey S. Weber · 2021 · Nature Reviews Drug Discovery
17. T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients
    Yaxian Kong, Liuluan Zhu, Todd D. Schell, Jianhong Zhang, David F. Claxton, William Christopher Ehmann, Witold B. Rybka, Melissa R. George, Hui Zeng, Hong Zheng · 2016 · Clinical Cancer Research
18. PD-1 and PD-L1 antibodies in cancer: current status and future directions
    Arjun Vasant Balar, Jeffrey S. Weber · 2017 · Cancer Immunology Immunotherapy
19. Immuno-Oncology: Emerging Targets and Combination Therapies
    Henry T. Marshall, Mustafa B.A. Djamgoz · 2018 · Frontiers in Oncology
20. Tailoring Nanomaterials for Targeting Tumor‐Associated Macrophages
    Muhammad Ovais, Mengyu Guo, Chunying Chen · 2019 · Advanced Materials
21. Safety of combining radiotherapy with immune-checkpoint inhibition
    William L. Hwang, Luke Pike, Trevor Joseph Royce, Brandon Arvin Virgil Mahal, Jay S. Loeffler · 2018 · Nature Reviews Clinical Oncology
22. The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment
    Haist, Maximilian, Stege, Henner, Grabbe, Stephan, Bros, Matthias · 2021 · Cancers
23. Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
    Ioannis Zerdes, Alexios Matikas, Jonas C. S. Bergh, George Z. Rassidakis, Theodoros Foukakis · 2018 · Oncogene
24. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
    Abdel-Wahab, Noha, Safa, Houssein, Abudayyeh, Ala, Johnson, Daniel H., Trinh, Van Anh, Zobniw, Chrystia M., Lin, Heather, Wong, Michael K., Abdelrahim, Maen, Gaber, A. Osama et al. · 2019 · Journal for ImmunoTherapy of Cancer
25. B7-H3/CD276: An Emerging Cancer Immunotherapy
    Wu-Tong Zhou, Weilin Jin · 2021 · Frontiers in Immunology
26. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1 -mutated breast cancer
    Emma Nolan, Peter Stephen Savas, Antonia N. Policheni, Phillip Kevin Darcy, François Vaillant, Christopher Mintoff, Sathana Dushyanthen, Mariam Mansour, Jia‐Min Pang, Stephen B. Fox et al. · 2017 · Science Translational Medicine
27. Immunosuppressive Activities of Adenosine in Cancer
    Allard, Bertrand, Beavis, Paul A, Darcy, Phillip K, Stagg, John · 2016 · Current Opinion in Pharmacology
28. Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression
    Saleh, Reem, Elkord, Eyad · 2020 · Seminars in Cancer Biology
29. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment
    Stefani Spranger · 2016 · International Immunology
30. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022
    Claus Garbe, Teresa Maria Santos Amaral, Ketty Peris, Axel Hauschild, Petr Arenberger, Nicole Basset‐Séguin, Lars Bastholt, Veronique A. Bataille, V. del Mármol, Brigitte Dréno et al. · 2022 · European Journal of Cancer
31. Immune mechanisms of toxicity from checkpoint inhibitors
    S. Jennifer Wang, Stephanie K. Dougan, Michael Lawrence Dougan · 2023 · Trends in cancer
32. The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma
    Maria Del Castillo, Fabián Andrés Rosas Romero, Esther Argüello, Chrisann Kyi, Michael Andrew Postow, Gil Redelman‐Sidi · 2016 · Clinical Infectious Diseases
33. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study
    Smita S. Chandran, Robert P. T. Somerville, James Chih-Hsin Yang, Richard Mark Sherry, Christopher Austin Klebanoff, Stephanie L. Goff, John R. Wunderlich, David N. Danforth, Daniel A. Zlott, Biman C. Paria et al. · 2017 · The Lancet Oncology
34. A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor–Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention
    Wei, Spencer C., Meijers, Wouter C., Axelrod, Margaret L., Anang, Nana-Ama A.S., Screever, Elles M., Wescott, Elizabeth C., Johnson, Douglas B., Whitley, Elizabeth, Lehmann, Lorenz, Courand, Pierre-Yves et al. · 2021 · Cancer Discovery
35. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management
    Mario Sznol, Michael Andrew Postow, Marianne J Davies, Anna C. Pavlick, Elizabeth R. Plimack, Montaser F. Shaheen, Colleen Veloski, Caroline Robert · 2017 · Cancer Treatment Reviews
36. PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
    Zijun Yidan Xu-Monette, Mingzhi Zhang, Jianyong Li, Ken H. Young · 2017 · Frontiers in Immunology
37. Resistance to Checkpoint Inhibition in Cancer Immunotherapy
    Luisa Barrueto, Francheska Caminero, Lindsay Cash, Courtney Makris, Purushottam Lamichhane, Rahul R. Deshmukh · 2020 · Translational Oncology
38. Pembrolizumab for the treatment of non-small cell lung cancer
    Sung Hee Lim, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn · 2016 · Expert Opinion on Biological Therapy
39. Trial watch: STING agonists in cancer therapy
    Le Naour, Julie, Zitvogel, Laurence, Galluzzi, Lorenzo, Vacchelli, Erika, Kroemer, Guido · 2020 · OncoImmunology
40. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
    Mario Sznol, Pier Francesco Ferrucci, David Hogg, Michael B. Atkins, Pascal Wolter, Massimo Guidoboni, Célèste Lebbé, John M. Kirkwood, Jacob Schachter, Gregory A. Daniels et al. · 2017 · Journal of Clinical Oncology
41. Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
    Ju‐Yeun Lee, Hyun Tae Lee, Woori Shin, Jongseok Chae, Jaemo Choi, Sung Hyun Kim, Heejin Lim, Tae Won Heo, Kyeong Young Park, Yeon Ji Lee et al. · 2016 · Nature Communications
42. Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook
    Chao Wang, Yanqi Ye, Quanyin Hu, Adriano Bellotti, Zhen Gu · 2017 · Advanced Materials
43. Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
    Jin‐Yu Sun, Dengke Zhang, Songquan Wu, Min Xu, Xiao Zhou, Xiaojie Lu, Jiansong Ji · 2020 · Biomarker Research
44. Overall Survival and Durable Responses in Patients With BRAF V600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
    Georgina Venetia Long, Jeffrey S. Weber, Jeffrey R. Infante, Kevin B. Kim, ADIL I. DAUD, Rene C. Gonzalez, Jeffrey Alan Sosman, Omid Hamid, Lynn Mara Schuchter, Jonathan Simon Cebon et al. · 2016 · Journal of Clinical Oncology
45. Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017
    Selma Ugurel, Joachim Röhmel, Paolo A. Ascierto, Keith T. Flaherty, Jean‐Jacques Grob, Axel Hauschild, James Larkin, Georgina Venetia Long, Paul C. Lorigan, Grant A. McArthur et al. · 2017 · European Journal of Cancer
46. Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
    Liting Guo, Haijun Zhang, Baoan Chen · 2017 · Journal of Cancer
47. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity
    Nan Guo Ring, Dietmar Herndler‐Brandstetter, Kipp Weiskopf, Liang Shan, Jens-Peter Volkmer, Benson M. George, Melanie Lietzenmayer, Kelly Marie McKenna, Tejaswitha Jairaj Naik, Aaron McCarty et al. · 2017 · Proceedings of the National Academy of Sciences
48. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities
    Pauken, Kristen E., Dougan, Michael, Rose, Noel R., Lichtman, Andrew H., Sharpe, Arlene H. · 2019 · Trends in Immunology
49. Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
    Paul E. Hughes, Sean R. Caenepeel, Lawren C. Wu · 2016 · Trends in Immunology
50. Combination of fucoidan-based magnetic nanoparticles and immunomodulators enhances tumour-localized immunotherapy
    Chih‐Sheng Chiang, Yu‐Jung Lin, Rachel Lee, Yen‐Ho Lai, Hung‐Wei Cheng, Chia‐Hung Hsieh, Woei‐Cherng Shyu, San‐Yuan Chen · 2018 · Nature Nanotechnology
51. Immunotherapy of Melanoma: Facts and Hopes
    Sarah Ann Weiss, Jedd D. Wolchok, Mario Sznol · 2019 · Clinical Cancer Research
52. Immunotherapy in melanoma: Recent advances and future directions
    Cindy Franklin, Elisabeth Livingstone, Alexander Roesch, Bastian Schilling, Dirk Schadendorf · 2016 · European Journal of Surgical Oncology
53. A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer
    Liu, Zhixian, Li, Mengyuan, Jiang, Zehang, Wang, Xiaosheng · 2018 · Translational Oncology
54. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management
    Marnix H. Geukes Foppen, Elisa A. Rozeman, Sandra van Wilpe, Cindy Postma, Pétur Snæbjörnsson, Johannes V. van Thienen, Monique Esther van Leerdam, Michel M. van den Heuvel, Christian U. Blank, Jolanda M. van Dieren et al. · 2018 · ESMO Open
55. PD1 signal transduction pathways in T cells
    Hugo Arasanz, María Gato, Miren Zuazo, María Ibáñez-Vea, Karine Breckpot, Grazyna T. Kochan, David Escors · 2017 · Oncotarget
56. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis
    James Larkin, Bartosz Chmielowski, Christopher D. Lao, Frank Stephen Hodi, William Howard Sharfman, Jeffrey S. Weber, Karijn P.M. Suijkerbuijk, Sérgio Jobim Azevedo, Hewei Li, Daniel S. Reshef et al. · 2017 · The Oncologist
57. Immune system and melanoma biology: a balance between immunosurveillance and immune escape
    Anna Maria Passarelli, Francesco Mannavola, Luigia Stefania Stucci, Marco Tucci, Francesco Silvestris · 2017 · Oncotarget
58. LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes
    Yayi He, Hui Yu, Leslie M. Rozeboom, Christopher J. Rivard, Kim E. Ellison, Rafał Dziadziuszko, Kenichi Suda, Shengxiang Ren, Chunyan Wu, Likun Hou et al. · 2017 · Journal of Thoracic Oncology
59. Systemic Therapy for Melanoma: ASCO Guideline
    Rahul Seth, Hans J. Messersmith, Varinder Kaur, John M. Kirkwood, Ragini Reiney Kudchadkar, Jennifer Leigh McQuade, Anthony F. Provenzano, Umang Swami, Jeffrey S. Weber, Krishna Chaitanya Alluri et al. · 2020 · Journal of Clinical Oncology
60. Immunotherapy in Melanoma: Recent Advances and Future Directions
    Andrew Knight, Lilit Karapetyan, John M. Kirkwood · 2023 · Cancers
61. The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
    Liève Brochez, Inès Chevolet, Vibeke Krüse · 2017 · European Journal of Cancer
62. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
    Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen Anthony Boorjian, Mark K. Buyyounouski, Peter E. Clark, Tracy M. Downs, Jason Alexander Efstathiou, Thomas W. Flaig, Terence W. Friedlander et al. · 2017 · Journal of the National Comprehensive Cancer Network
63. CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes
    Moritz Rapp, Maximilian W. M. Wintergerst, Wolfgang Gerhard Kunz, Viola Katharina Vetter, Maximilian M. L. Knott, Dominik Lisowski, Sascha Haubner, Stefan Moder, Raffael Thaler, Stephan Eiber et al. · 2019 · The Journal of Experimental Medicine
64. The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View
    João B. Xavier, Vincent Bensan Young, Joseph D. Skufca, Fiona Ginty, Traci L. Testerman, Alexander T. Pearson, Paul Macklin, Amir Mitchell, Ilya Shmulevich, Lei Xie et al. · 2020 · Trends in cancer
65. An Immune-Related Gene Prognostic Index for Head and Neck Squamous Cell Carcinoma
    Yue Chen, Zhiyong Li, Guan‐Qun Zhou, Ying Hao Sun · 2020 · Clinical Cancer Research
66. Promises and challenges of adoptive T-cell therapies for solid tumours
    Matteo Morotti, Ashwag Albukhari, Abdulkhaliq Alsaadi, Mara Artibani, James D. Brenton, Stuart M. Curbishley, Tao Dong, Michael Loran Dustin, Zhiyuan Hu, Nicholas McGranahan et al. · 2021 · British Journal of Cancer
67. Immune checkpoint inhibitor-induced colitis: A comprehensive review
    Aniruddh Som, Rohan H. Mandaliya, Dana Alsaadi, Maham Farshidpour, Aline Charabaty, Nidhi Malhotra, Mark C Mattar · 2019 · World Journal of Clinical Cases
68. Immunotherapy for hepatocellular carcinoma
    Yin Zongyi, Xiaowu Li · 2019 · Cancer Letters
69. Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
    Liping Pei, Yang Liu, Lin Liu, Shuochen Gao, Xueyan Gao, Yudi Feng, Zhenqiang Sun, Yan Zhang, Chengzeng Wang · 2023 · Molecular Cancer
70. 3D microfluidic <i>ex vivo</i> culture of organotypic tumor spheroids to model immune checkpoint blockade
    Aref, Amir R., Campisi, Marco, Ivanova, Elena, Portell, Andrew, Larios, Dalia, Piel, Brandon P., Mathur, Natasha, Zhou, Chensheng, Coakley, Raven Vlahos, Bartels, Alan et al. · 2018 · Lab on a Chip
71. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
    Vincent Sibaud, Nicolás Meyer, Laurence Lamant, Émmanuelle Vigarios, Julien Mazières, Jean Pierre Delord · 2016 · Current Opinion in Oncology
72. Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
    Klaus Okkenhaug, Mariona Graupera, Bart Vanhaesebroeck · 2016 · Cancer Discovery
73. Driving gene-engineered T cell immunotherapy of cancer
    Laura A Johnson, Carl H. June · 2016 · Cell Research
74. Enterocolitis due to immune checkpoint inhibitors: a systematic review
    Émilie Soularue, Patricia Lepage, Jean Frédéric Colombel, Clélia Coutzac, David M. Faleck, Lysiane Marthey, Michael Collins, Nathalie Chaput, Caroline Robert, Franck Carbonnel · 2018 · Gut
75. VSIG ‐3 as a ligand of VISTA inhibits human T‐cell function
    Jinghua Wang, Guoping Wu, Brian Manick, Vida Hernandez, Mark Renelt, Christian Erickson, Joanna Guan, Ravinder Singh, Simone Rollins, Alicia Solorz et al. · 2018 · Immunology
76. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1–insensitive models of triple-negative breast cancer
    Ning Cheng, Rebekah Watkins-Schulz, Robert D. Junkins, Clément N. David, Brandon M. Johnson, Stephanie A. Montgomery, Kevin J. Peine, David B. Darr, Hong Yuan, Karen P. McKinnon et al. · 2018 · JCI Insight
77. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature
    Lavinia Anne Spain, Gerard Walls, Maximilian Julve, Karen O’Meara, T. Schmid, E. Kalaitzaki, Samra Turajlic, Martin Eric Gore, Jeremy H. Rees, James Larkin · 2016 · Annals of Oncology
78. Patterns of Response and Progression to Immunotherapy
    Édith Borcoman, Amara Gayathri Nandikolla, Georgina Venetia Long, Sanjay Goel, Christophe Le Tourneau · 2018 · American Society of Clinical Oncology Educational Book
79. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
    Paul B. Chapman, Caroline Robert, James Larkin, John B.A.G. Haanen, Antoni Ribas, David Hogg, Omid Hamid, Paolo A. Ascierto, Alessandro Testori, Paul C. Lorigan et al. · 2017 · Annals of Oncology
80. Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
    Marc Oliva, Anna Spreafico, Miren Taberna, Laia Alemany, Bryan A. Coburn, Ricard Mesı́a, Lillian L. Siu · 2018 · Annals of Oncology
81. Enrollment of Racial Minorities in Clinical Trials: Old Problem Assumes New Urgency in the Age of Immunotherapy
    Bassel Nazha, Manoj Kumar Mishra, Rebecca Davis Pentz, Taofeek Kunle Owonikoko · 2019 · American Society of Clinical Oncology Educational Book
82. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
    Yuchen Wang, Hao Zhang, Chao Liu, Zeyu Wang, Wantao Wu, Nan Zhang, Longbo Zhang, Jason J. Hu, Peng Luo, Jian Zhang et al. · 2022 · Journal of Hematology & Oncology
83. Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold
    Vredevoogd, David W., Kuilman, Thomas, Ligtenberg, Maarten A., Boshuizen, Julia, Stecker, Kelly E., de Bruijn, Beaunelle, Krijgsman, Oscar, Huang, Xinyao, Kenski, Juliana C.N., Lacroix, Ruben et al. · 2019 · Cell
84. Novel immunotherapies in lymphoid malignancies
    Connie Lee Batlevi, Eri Matsuki, Renier J. Brentjens, Anas Younes · 2015 · Nature Reviews Clinical Oncology
85. A Convergence-Based Framework for Cancer Drug Resistance
    Konieczkowski, David J., Johannessen, Cory M., Garraway, Levi A. · 2018 · Cancer Cell
86. A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
    Petros Fessas, Hassal Lee, Shinji Ikemizu, Tobias Janowitz · 2017 · Seminars in Oncology
87. Gut microbiome and cancer immunotherapy
    Weina Li, Yu Deng, Qian Chu, Peng Zhang · 2019 · Cancer Letters
88. Releasing the Brakes on Cancer Immunotherapy
    Antoni Ribas · 2015 · New England Journal of Medicine
89. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal
    Patrick Alexander Ott, Sarina Anne Piha-Paul, Pamela N. Münster, Michael Jon Pishvaian, Emilie M.J. van Brummelen, Roger B. Cohen, Carlos Gomez‐Roca, Samuel Ejadi, Mark N. Stein, Emily W. Chan et al. · 2017 · Annals of Oncology
90. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome
    Simpson, Rebecca C., Shanahan, Erin R., Batten, Marcel, Reijers, Irene L. M., Read, Mark, Silva, Ines P., Versluis, Judith M., Ribeiro, Rosilene, Angelatos, Alexandra S., Tan, Jian et al. · 2022 · Nature Medicine
91. Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non–Small-Cell Lung Cancer: A Review
    Sacher, Adrian G., Gandhi, Leena · 2016 · JAMA Oncology
92. PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients
    Aung Naing, Jeffrey R. Infante, Kyriakos P. Papadopoulos, Ivan H. Chan, Cong Shen, Navneet P. Ratti, Bianca Rojo, Karen A. Autio, Deborah J. L. Wong, Manish R. Patel et al. · 2018 · Cancer Cell
93. Systemic treatments for metastatic cutaneous melanoma
    Sandro Pasquali, Andreas V. Hadjinicolaou, Vanna Chiarion‐Sileni, Carlo Riccardo Rossi, Simone Mocellin M. D · 2018 · Cochrane Database of Systematic Reviews
94. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
    Andressa S. Laino, David Michael Woods, Melinda Vassallo, Xiaozhong Qian, Hao Tang, Megan Wind‐Rotolo, Jeffrey S. Weber · 2020 · Journal for ImmunoTherapy of Cancer
95. Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma
    Caroline Robert, Georgina Venetia Long, Benjamin Brady, Caroline Dutriaux, Anna Maria Di Giacomo, Laurent Mortier, Piotr Lukasz Rutkowski, Jessica C. Hassel, Catriona M. McNeil, Ewa Kalinka‐Warzocha et al. · 2020 · Journal of Clinical Oncology
96. Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions
    Antje Sucker, Fang Zhao, Natalia Pieper, Christina Heeke, Raffaela Maltaner, Nadine Stadtler, Birgit Real, Nicola Bielefeld, Sebastian Howe, Benjamin Weide et al. · 2017 · Nature Communications
97. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study
    Michael Joseph Boyer, Mehmet Alı Nahıt Şendur, Delvys Rodríguez‐Abreu, Keunchil Park, Dae Ho Lee, İrfan Çiçin, Perran Fulden Yumuk, Francesco Orlandi, Ticiana A.B. Leal, Olivier Molinier et al. · 2021 · Journal of Clinical Oncology
98. Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events
    Elisa González-Rodríguez, Delvys Rodríguez‐Abreu, on behalf of the Spanish Group for Cancer Immuno-Biotherapy (GETICA) · 2016 · The Oncologist
99. Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
    Hyun Tae Lee, Ju‐Yeun Lee, Heejin Lim, Sang Hyung Lee, Yu Jeong Moon, Hyo Jeong Pyo, Seong Eon Ryu, Woori Shin, Yong-Seok Heo · 2017 · Scientific Reports
100. Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade
     Xiaoming Dai, Xia Bu, Yang Gao, Jianping Guo, Jia Hu, Cong Jiang, Zhao Zhang, Kexin Xu, Jinzhi Duan, Shaohui He et al. · 2021 · Molecular Cell